Regeneron Pharmaceuticals, Inc. (REGN) Earnings Call Transcripts
Regeneron Pharmaceuticals, Inc.'s Latest Earnings Call - Q3 FY2026
In the third quarter of 2026, Regeneron Pharmaceuticals reported a significant revenue increase of 36% year-over-year, reaching $5.1 billion, alongside a 70% growth in non-GAAP earnings per share to $20.07. The strong performance was driven by record sales of key products, particularly Dupixent, which generated $6.5 billion in global net sales, marking a 35% increase year-over-year. Management maintained a positive outlook, highlighting ongoing momentum in their commercial execution and pipeline advancements, while also signaling an increase in R&D expenses for 2027 to support future growth initiatives.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $5.1 billion |
| Non-GAAP EPS | $20.07 |
| EYLEA HD U.S. Net Sales | $700 million |
| Collaboration Revenue | $2.7 billion (null) |
| Free Cash Flow | $2.9 billion (null) |
Guidance from management
Management expects to increase R&D expenses by a mid-teens percentage in 2027 compared to 2026 and anticipates continued growth in key products, particularly Dupixent and EYLEA HD, despite competitive pressures.
What management said
Chris, this concludes our prepared remarks. We will now open up the call for Q&A. To ensure we are able to address as many questions as possible, we will answer one question from each caller before moving to the next. Shannon, can we please go to our first question.
Sure. Very happy to make come in. So we certainly have a very talented neurology team at Regeneron. Very pleased with the caliber experience that the team has in neurology with other programs, and now we're really excited to bring that to Regeneron. As we mentioned, PDUFA date in November, very exciting. So launch activities, preparation are well underway. I'm not going to say a lot about launch strategy, but delight...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for EYLEA, particularly with the introduction of biosimilars. There were also questions about the potential for Dupixent's pipeline expansion to meet unmet needs in the market.
Main topics on the call
- Record Sales of Dupixent — Dupixent achieved global net sales of $6.5 billion, up 35% year-over-year, with U.S. sales exceeding $5 billion for the first time, driven by strong demand across all indications. Management noted, "Dupixent is the leadi...
- Strong Performance of EYLEA HD — EYLEA HD net sales in the U.S. reached approximately $700 million, up 62% from a year ago. This growth reflects a 20% sequential increase in physician unit demand, indicating strong market acceptance. Marion McCourt stat...
- Pipeline Advancements — Regeneron highlighted several promising pipeline programs, including cemdisiran for generalized myasthenia gravis, with an FDA decision expected in November 2026. The company is optimistic about its potential, stating, "...
- Expansion of Sanofi Alliance — Regeneron announced an expansion of its collaboration with Sanofi to develop next-generation long-acting antibodies, which will be co-funded and co-commercialized. This strategic move aims to leverage Dupixent's success ...
Read the full Regeneron Pharmaceuticals, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 139 calls on record spanning January 13, 2020 to October 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 139 Regeneron Pharmaceuticals, Inc. earnings call transcripts on record, spanning January 13, 2020 to October 30, 2026. Based on this history, Regeneron Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated October 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- REGN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 139
- First call
- January 13, 2020
- Most recent
- October 30, 2026
- Reporting cadence
- quarterly